Technology | 2023.08.09
STORM Therapeutics to present the discovery of lead clinical candidate STC-15 at the American Chemical Society Fall 2023 Conference
STORM\'s lead programme is the first RNA methyltransferase inhibitor to enter clinical development CAMBRIDGE, England, Aug. 9, 2023 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies...
For more information, please visit
https://www.prnewswire.com/news-releases[...]2023-conference-301896181.html
Follow us on
Instagram is adding automatic in-app text translation - The Verge views: 1553
Instagram is adding automatic in-app text translation - The Verge views: 1506